- Executive branch pressure influences the FDA to implement strong regulatory crackdowns.
- The U.S. biotech industry is concerned that excessive and slow bureaucratic regulation is dulling its competitive edge.
The US biotech industry is facing unprecedented pressure from growing Chinese competition, leading to government actions like the Biosecure Act and tariffs on biological products.
1 report, 1 independent
Updated May 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The US biotech industry is facing unprecedented pressure from growing Chinese competition, leading to government actions like the Biosecure Act and tariffs on biological products.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- NDAA directs OMB to maintain an expanded list, restricting U.S. procurement from PRC firms, including genomics company BGI Group.Sub-event
US government actions (tariffs, Biosecure Act) and NIH layoffs are impacting the US biotech sector due to Chinese competition.1 source
Keep exploring
The entities involved
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China